» Articles » PMID: 3297309

C-myc Amplification and Expression in Newly Established Human Osteosarcoma Cell Lines

Overview
Journal Cancer Res
Specialty Oncology
Date 1987 Jul 15
PMID 3297309
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Three cell lines were isolated from a patient with osteosarcoma of the femur. These lines were obtained from the primary neoplasm before (HTLA145) and after (HTLA161) chemotherapy and from a metastasis of the lung (HTLA195) in the same patient. The three cell lines exhibited a similar morphology in culture and formed tumors in nude mice which demonstrated a histopathology similar to that which had been observed in the patient. High expression of the genes coding for the alpha-1 and alpha-2 chain of collagen Type I was found in vitro and in s.c. tumors growing in nude mice. The c-myc protooncogene was amplified in all three cell lines and extensive expression of c-myc was found in vitro and in vivo. No heterogeneity in regard to c-myc expression in vivo was detected by in situ localization in tumors growing in nude mice.

Citing Articles

The splicing factor proline and glutamine rich promotes the growth of osteosarcoma via the c-Myc signaling pathway.

Mao L, Jiang P, Lei X, Zhang B, Zhong X, Yin Z Am J Cancer Res. 2023; 13(6):2488-2503.

PMID: 37424803 PMC: 10326564.


Comparative analysis of genome-wide DNA methylation identifies patterns that associate with conserved transcriptional programs in osteosarcoma.

Mills L, Scott M, Shah P, Cunanan A, Deshpande A, Auch B Bone. 2020; 158:115716.

PMID: 33127576 PMC: 8076342. DOI: 10.1016/j.bone.2020.115716.


MicroRNAs in the pathobiology of sarcomas.

Sarver A, Subramanian S Lab Invest. 2015; 95(9):987-94.

PMID: 26121318 DOI: 10.1038/labinvest.2015.81.


Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma.

Lee D, Qi J, Bradner J, Said J, Doan N, Forscher C Int J Cancer. 2014; 136(9):2055-64.

PMID: 25307878 PMC: 4824295. DOI: 10.1002/ijc.29269.


Canine osteosarcoma cells exhibit resistance to aurora kinase inhibitors.

Cannon C, Pozniak J, Scott M, Ito D, Gorden B, Graef A Vet Comp Oncol. 2013; 13(1):48-59.

PMID: 23410058 PMC: 4672990. DOI: 10.1111/vco.12018.